Company attributes
Other attributes
Applied DNA Sciences is a company that looks to provide botanical DNA-based solutions. The company was founded in 1983 by James A. Hayward, and is headquartered in Stony Brook, New York, United States. Applied DNA Sciences provides molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
The company's DNA-based technology is utilized in a variety of industries including: textiles/fashion, wine, musical instruments, and electronics. Luxury goods manufacturers use these products to identify counterfeit consumer goods and to ensure their products' authenticity, helping, in part, to stem the flow of counterfeit goods and eliminate the slavery that is often implicit in the production of fake goods. Applied DNA Sciences' products were vetted in a pilot program by the Defense Logistics Agency of the Department of Defense, where their technology succeeded in distinguishing between counterfeit and authentic microchips 100% of the time.
Applied DNA Sciences is interested in producing pharmaceuticals and authentication technologies, and a platform for cannabis that provides customers a proof of product origin.
COVID-19
The company has worked with its subsidiaries, LineaRx and Takis Biotech to form a joint venture to develop a DNA vaccine as a treatment for coronavirus. The strategy for the development of the vaccine will be to utilize a Polymerase Chain Reaction-based DNA manufacturing technology. This technology will allow quicker production speeds, and wont require antibiotics or bacterial contaminants. The vaccine can be inserted into the patient's genome, however animal testing must be completed first.
Applied DNA Science looks to provide large-scale production of the effective vaccine, and is meant to be safer than other DNA production platforms. The company claims that the coronavirus mutates at rapid rates. Therefor the company believes the benefit of the PCR-produced linear DNA solution is the most rapid, putative vaccine that can accommodate mutational changes in the coronavirus.
